Day 2 – Sept 24, 2026Thursday, September 24, 2026 - ET (Eastern Time, GMT-05:00)

Getting partnership structure right is the difference between momentum and gridlock. This panel distils how to architect win–win agreements that align incentives from discovery to commercialization. Panelists will share negotiation playbooks and conflict-avoidance tools—from red-line frameworks and scenario modelling to escalation ladders, JSC charters, and mediation/arbitration clauses—so you can prevent disputes before they start and resolve them fast when they do. Attendees will leave with concrete tactics to structure resilient partnerships that create sustained value for both sides.

• Key elements of structuring agreements for mutual benefit in biopharma partnerships

• Balancing intellectual property, financial terms, and operational responsibilities

• Best practices for negotiation and conflict resolution to ensure long-term success

This panel will examine how private equity partners accelerate biopharma growth by providing expansion capital and infrastructure, implementing operational playbooks to boost efficiency and scale, and orchestrating strategic M&A to strengthen pipelines and market position. Panelists will share practical examples of value-creation strategies, integration challenges, and metrics that signal successful scaling — followed by audience Q&A on lessons for founders, executives, and investors.

• Providing capital for expansion and infrastructure development

• Driving operational efficiency and strategic growth initiatives

• Facilitating mergers, acquisitions, and market consolidation

• Which emerging modalities are overhyped and which are underappreciated?

• What are the principal technical and manufacturing barriers that must be solved?

• How can early-stage companies demonstrably de-risk novel mechanisms to attract investors and strategic partners?

• Selecting the right first assets and establishing product cadence: indication fit, tractable biology, and crisp value inflections

• Engineering proof-of-platform: translational biomarkers, modular CMC, and trial designs that replicate across programs

• Scaling the engine: portfolio allocation, co-development and spinouts, and milestone/royalty structures that recycle capital

• Providing mentorship and resources to foster innovation

• Connecting startups with investors and industry networks

• Accelerating development through shared infrastructure and expertise

AI is rewriting the biotech playbook—but capital still chases credible paths to value. This panel brings together founders and investors to separate signal from noise: what makes an AI-enabled company truly investable, how to translate platform promise into near-term milestones, and where partnerships, capital strategy, and governance turn speed into durable advantage. Expect pragmatic perspectives on timelines that travel, evidence that resonates, and deal structures that keep optionality high.

• What “investable” looks like: crisp problem focus, believable timelines to IND, and milestones that de-risk science and business

• Proving the edge without the hype: transparent validation, real-world use cases, and data moats that compound over time

• Smart capital and partnerships: sequencing raise sizes, syndicate strategy, and partner moments that extend runway and preserve upside

The next chapter of biotech won’t be defined by a single breakthrough, but by the convergence of computation, engineered biology, and new models of capital and collaboration. This closing keynote brings visionaries across science, finance, and policy to chart how we turn exponential tools into durable value: resilient companies that weather cycles, programs that move faster with greater certainty, and a health system ready to adopt what we build. It’s a blueprint for scaling patient impact and investor outcomes—responsibly, repeatably, and at global reach.

• Convergence that compounds: AI, automation, and engineered biology aligning to compress discovery-to-clinic while raising the quality bar

• A new pact with the market: milestones that travel, outcome-based adoption, and deal constructs that balance speed, risk, and upside

• The leadership agenda: talent, governance, and ethics that build resilient platforms—and companies—that outperform across cycles